EU gives narrower label to Apellis, Sobi’s PNH drug
pharmaphorum
DECEMBER 15, 2021
Apellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in Europe, with a more restricted label than in the US. The post EU gives narrower label to Apellis, Sobi’s PNH drug appeared first on.
Let's personalize your content